VRTX Vertex Pharmaceuticals

company

SEC Filings & Insider Trading Activity 2026

Management Discussion & Analysis

• • Revenue $12.0B in 2025, up 9% YoY from $11.0B in 2024; TRIKAFTA/KAFTRIO sales $10.3B (1% increase), ALYFTREK $837.8M launched in 2025
• • Operating margin approx. 34.7% in 2025 vs 13.8% cost of sales (13.8% of net product revenues), slight improvement from 13.9% in 2024; R&D + SG&A expenses $5.7B up from $5.1B
• • Best performing segment: TRIKAFTA/KAFTRIO revenues $10.31B (+1%); Worst: Newly launched CASGEVY $115.8M and JOURNAVX $59.6M, small but growing
• • Cash, cash equivalents, marketable securities increased to $12.3B in 2025 from $11.2B in 2024; repurchased shares partially offset; R&D expenses $3.91B (+8%), cost of sales $1.65B (+8%)
• • 2026 Outlook: Continued CF revenue growth led by ALYFTREK globally, increased CASGEVY and JOURNAVX revenues; pipeline regulatory submissions expected H1 2026; watch ongoing royalty dispute on ALYFTREK royalty rate

Business Overview

• • Core business model: Biopharmaceutical company focused on developing and commercializing transformative medicines
• • Emphasis on enhanced cybersecurity governance with dedicated CISO and quarterly Board updates
• • Cybersecurity led by CISO with 35+ years’ experience, including federal advisory roles, highlighting heightened focus on cyber risk
• • Cybersecurity team holding top certifications conducts regular vulnerability scans, penetration tests, and threat intelligence analysis
• • Cybersecurity risk oversight integrated into executive management reporting chain up to CEO, reflecting strategic prioritization

Risk Factors

• • Regulatory risk: Impact of Colorado PDAB affordability review on TRIKAFTA pricing with potential upper payment limits under the 2023 state program
• • Macroeconomic risk: Ex-U.S. reimbursement delays and government cost-containment efforts impacting pricing and revenue in various international markets
• • Operational risk: CASGEVY manufacturing cost significantly higher as a percentage of revenue versus CF medicines, with complex cell collection and administration processes
• • Competitive risk: Pressure from lower-cost and advanced competitors in acute and peripheral neuropathic pain markets threatening uptake of JOURNAVX
• • Financial risk: Concentrated revenue dependence on CF medicines, exposing business to risks from manufacturing, safety, market acceptance, and pricing challenges

What are the latest VRTX SEC filings in 2026?

Vertex Pharmaceuticals (VRTX) has filed a 10-K annual report on February 13, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did VRTX file its most recent 10-K annual report?

Vertex Pharmaceuticals (VRTX) filed its most recent 10-K annual report on February 13, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view VRTX 10-Q quarterly reports?

Vertex Pharmaceuticals (VRTX)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every VRTX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has VRTX filed recently?

Vertex Pharmaceuticals (VRTX)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find VRTX insider trading activity (Form 4)?

SignalX aggregates every VRTX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does VRTX file with the SEC?

Vertex Pharmaceuticals (VRTX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VRTX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Vertex Pharmaceuticals (VRTX).

What is VRTX's SEC CIK number?

Vertex Pharmaceuticals (VRTX)'s SEC CIK (Central Index Key) number is 875320. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 875320 to look up all VRTX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find VRTX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Vertex Pharmaceuticals (VRTX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.